Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 286.00
Bid: 287.00
Ask: 290.00
Change: -2.00 (-0.69%)
Spread: 3.00 (1.045%)
Open: 290.00
High: 290.00
Low: 286.00
Prev. Close: 288.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Hutchmed sinks on US FDA drug rejection

Tue, 03rd May 2022 11:29

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Vast Resources PLC, up 50% at 0.51 pence, 12-month range 0.08p-10.00p. The Romania and Zimbabwe-focused miner says revenue more than doubled to USD2.3 million in the first quarter from USD970,465 in the fourth quarter. Reports increase in tons milled and in dry-metric-ton production at the Baita Plai polymetallic mine in Romania.

----------

Eneraqua Technologies PLC, up 10% at 280.00p, up 1.1% from November listing price of 277.00p. The energy and water efficiency services provider wins contract from the Indian state government of Uttarakhand to reduce carbon emissions and improve water efficiency. The northern state has a population of over 10 million people. Contract is worth GBP900,000 from the state's Department of Horticulture will see Eneraqua supply systems to 340 horticultural farms across the state.

----------

AIM - LOSERS

----------

Hutchmed (China) Ltd, down 15% at 208.00p, 12-month range 202.50p-656.00p. The US Food & Drug Administration has rejected the drugmaker's surufatinib for treatment of pancreatic neuroendocrine tumours. In a complete response letter, the FDA said the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time". The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
4 Sep 2020 14:13

Hutchison Chi-Med begins latest trial of fruquintinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, said on Friday that it has initiated 'FRESCO-2' - a phase 3 registration study of 'fruquintinib' for the treatment of patients with metastatic colorectal cancer (CRC) in the US, Europe and Japan.

Read more
3 Sep 2020 21:27

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

Read more
10 Aug 2020 11:04

IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application

IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application

Read more
30 Jul 2020 17:56

IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth

IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth

Read more
28 Jul 2020 19:48

IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly

IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly

Read more
24 Jul 2020 15:45

Hutchison Chi-Med begins phase 1 study of 'HMPL-306'

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China.

Read more
24 Jul 2020 14:33

Chi-Med Trials Dual Inhibitor For Hematological Cancer

Chi-Med Trials Dual Inhibitor For Hematological Cancer

Read more
23 Jul 2020 16:03

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
23 Jul 2020 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
25 Jun 2020 15:08

Hutchison China Gets USD100 Million From US Private Equity Firm

Hutchison China Gets USD100 Million From US Private Equity Firm

Read more
18 Jun 2020 16:46

IN BRIEF: Hutchison China Gets US FDA Fast Track For Cancer Drug

IN BRIEF: Hutchison China Gets US FDA Fast Track For Cancer Drug

Read more
18 Jun 2020 09:18

Hutchison Chi-Med gets FDA fast track approval for fruquintinib

(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Thursday that the US Food and Drug Administration (FDA) has granted 'fast track designation' for the development of 'fruquintinib'.

Read more
9 Jun 2020 14:06

Hutchison Chi-Med venture to surrender unused land in Guangzhou

(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Tuesday that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company (HBYS) - its 50-50 joint venture with Guangzhou Baiyunshan Pharmaceutical Holdings - has agreed the planned return of its remaining 34 years land-use rights on its 30,000 square metre unused site in Tong He Town with the Guangzhou government.

Read more
9 Jun 2020 13:25

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

Read more
4 Jun 2020 13:19

UK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service

UK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.